36 results about "Decarboxylase inhibitor" patented technology

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose / fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose / fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and / or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.

Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and / or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and / or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and / or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

The invention provides a polygala tenuifolia extract for a parkinson's disease and a preparation method and an application of the polygala tenuifolia extract. The method comprises the following specific steps: taking a polygala tenuifolia material, adding 95% ethanol to soak over the night, carrying out heating reflux extraction and filtration and recovering ethanol until no alcohol taste in a vacuum condition to obtain an alcohol extract; adding water to soak the residual filter residues after filtration over the night, carrying out heating reflux extraction, filtration and vacuum concentration until a liquid extract to obtain a water extract; mixing the alcohol extract and the water extract at equal volume; adding petroleum ether, carrying out extracting and separating to remove the petroleum ether part; adding chloroform to the residual water solution, extracting and collecting a chloroform extracting solution; and concentrating the chloroform extracting solution until an extract, drying the extract in vacuum and crushing the product to obtain the effective part B. Through an in vitro anthropogenic dopa decarboxylase inhibitor screening model, the screened polygala tenuifolia effective part B has obvious anti-PD activity and can be applied to preparation of anti-PD medicines.

The present invention relates, generally to a method of determining and assessing L-3,4-dihydroxyphenylalanine (a.k.a., Levodopa; L-dopa; or LD) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled substrate, such as levodopa. The present invention is useful as an in vivo phenotype assay for individualizing LD / Carbidopa(CD) therapy in Parkinsons disease patients by optimizing the dose and timing of the dose of dopamine decarboxylase (DDC) inhibitor like CD for systemic suppression of dopamine metabolism by evaluating DDC enzyme activity using the metabolite 13CO2 in expired breath.

Use the general formula CH 3 (CH 2 ) x CH 2 (OCH 2 CH 2 ) n Polyglycol ethers of alkyl alcohols of OH, wherein x is 8-20 (wherein ceteareth-20, stearyl ether-20 and stearyl ether-100 are preferred), poloxamer 185, Poloxamer 407, N, N-dimethyldodecylamine N-oxide and mixtures thereof to improve the hair follicle transport and / or hair follicle residence time of certain water-soluble ornithine decarboxylase inhibitors, preferred inhibitors are 2-(difluoromethyl)-2,5-diaminovaleric acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixtures.

Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

The invention provides a polygala tenuifolia extract for a parkinson's disease and a preparation method and an application of the polygala tenuifolia extract. The method comprises the following specific steps: taking a polygala tenuifolia material, adding 95% ethanol to soak over the night, carrying out heating reflux extraction and filtration and recovering ethanol until no alcohol taste in a vacuum condition to obtain an alcohol extract; adding water to soak the residual filter residues after filtration over the night, carrying out heating reflux extraction, filtration and vacuum concentration until a liquid extract to obtain a water extract; mixing the alcohol extract and the water extract at equal volume; adding petroleum ether, carrying out extracting and separating to remove the petroleum ether part; adding chloroform to the residual water solution, extracting and collecting a chloroform extracting solution; and concentrating the chloroform extracting solution until an extract, drying the extract in vacuum and crushing the product to obtain the effective part B. Through an in vitro anthropogenic dopa decarboxylase inhibitor screening model, the screened polygala tenuifolia effective part B has obvious anti-PD activity and can be applied to preparation of anti-PD medicines.

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.